Finerenone Patent Expiration
Finerenone was first introduced by Bayer Healthcare Pharmaceuticals Inc
Finerenone Patents
Given below is the list of patents protecting Finerenone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Kerendia | USRE49826 | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient | Jul 29, 2035 | Bayer Hlthcare |
| Kerendia | US8436180 | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof | Aug 26, 2033 | Bayer Hlthcare |
Finerenone's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Finerenone:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
